Strides Pharma Science Reports Strong Financial Growth and Improved Operational Metrics in March 2025 Results

Strides Pharma Science has recently reported its financial results for the quarter ending March 2025, revealing notable developments within the company. The evaluation changes indicate a shift in the stock's score, which has adjusted to 21 from 24 over the past three months. The financial performance showcases significant growth in key metrics. Profit Before Tax less Other Income (PBT) reached Rs 121.82 crore, reflecting a substantial Year on Year (YoY) growth of 117.46%. Similarly, Profit After Tax (PAT) surged to Rs 104.26 crore, marking an impressive YoY increase of 301.8%. This quarter also saw the highest Operating Profit to Interest ratio in the last five quarters, recorded at 4.33 times, suggesting an improvement in the company's capacity to manage interest obligations. Net Sales for the quarter hit Rs 1,190.39 crore, the highest in the last five quarters, while Operating Profit (PBDIT) also peaked at Rs 217.86 crore. These results indicate a positive trend in Strides Pharma's operational performance, reflecting the company's ongoing efforts to enhance its financial standing. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.